NSAID use lowers risk of AMD development
23 giờ trước
Patients prescribed NSAIDs appear protected against the development of age-related macular degeneration (AMD) compared with nonusers, suggests a study.
A total of 634,794 patients who were prescribed NSAIDs (mean age 59.93 years) and 634,794 who were not prescribed NSAIDs (mean age 59.68 years) were included in the analysis.
Compared with nonusers, NSAID users demonstrated a lower risk of AMD development at 6 months (hazard ratio HR], 0.31, 95 percent confidence interval [CI], 0.27‒0.36), 1 year (HR, 0.36, 95 percent CI, 0.33‒0.39), 3 years (HR, 0.42, 95 percent CI, 0.40‒0.44), and 5 years (HR, 0.48, 95 percent CI, 0.47‒0.50) after the index date.
Furthermore, NSAID users enjoyed a protective benefit against AMD development compared with nonusers (HR, 0.58, 95 percent CI, 0.56‒0.59). Such protection was seen among patients who received aspirin (HR, 0.72, 95 percent CI, 0.69‒0.75) and those treated with nonselective cyclooxygenase-2 inhibitors (HR, 0.41, 95 percent CI, 0.36–0.46) compared with their respective nonusers.
After index NSAID prescription, the risk of AMD decreased for both nonexudative (HR, 0.56, 95 percent CI, 0.55‒0.58) and exudative (HR, 0.62, 95 percent CI, 0.59‒0.65) AMD subtypes.
In this retrospective cohort study, the authors used a de-identified multicentre electronic medical records database to identify patients who were prescribed NSAIDs with no prior AMD history. NSAID patients were then propensity score‒matched in a 1:1 ratio with a control group of randomly selected patients without a history of NSAID use, based on age, sex, race, and comorbidities.